UnknownNot Applicable

Anti-reflux Mucosectomy (ARMS) is a Useful Therapy for Refractory Gastroesophageal Reflux Disease (RGERD)

China20 participantsStarted 2017-08-20

Plain-language summary

Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Full sufficiency in literacy
✓. Be off proton pump inhibitor, antacids and prokinetics ≥ 2 weeks
✓. Refractory gastroesophageal reflux disease

Exclusion criteria

✕. Severe heart, lung, and cerebrovascular disease
✕. Severe hematopoietic system disease
✕. Abnormal blood coagulation function
✕. Oropharyngeal abnormalities
✕. Severe spine malformation
✕. In pregnancy and lactation at present, or plan to become pregnant within 2 years
✕. Severe inflammation or huge ulcers in stomach
✕. Mental and psychological disorde

What they're measuring

Improvement of symptoms

Timeframe: 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months

Trial details

NCT IDNCT03259191

SponsorRuihua Shi

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-11-20

Contact for this trial

Ruihua Shi, MD,PhD

+8613951799326 ruihuashi@126.com

View on ClinicalTrials.gov More Refractory Gastroesophageal Reflux Disease trials